ORIC Pharmaceuticals to Attend Major Investor Conferences
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC), a leading clinical stage oncology company focused on developing innovative treatments to combat therapeutic resistance, is making waves in the investment community. The company has announced its participation in several important investor conferences scheduled for November, aimed at enhancing shareholder engagement and transparency.
Key Events on the Horizon
During this pivotal month, ORIC Pharmaceuticals is set to engage with investors through two notable events:
Guggenheim's Inaugural Healthcare Innovation Conference
On the first day of the conference, ORIC's management team will participate in a fireside chat scheduled for November 11. This event will provide a unique platform for discussing their strategic vision, highlighting innovative projects, and addressing questions from investors.
Jefferies London Healthcare Conference
Following the Guggenheim event, ORIC will also be featured at the Jefferies London Healthcare Conference on November 21. This is another opportunity to connect with investors and share insights into the progress of their groundbreaking oncology therapies.
Live Broadcasts and Availability
Both discussions from the conferences will be broadcast live, allowing a broader audience to participate and gain insights into ORIC Pharmaceuticals' operations. Interested investors can find links to the live webcasts on the company's official website, where recordings will remain accessible for 90 days post-event.
Understanding ORIC Pharmaceuticals
Founded in California, ORIC Pharmaceuticals is dedicated to changing the landscape of cancer treatment by developing therapies that overcome resistance mechanisms. Their pipeline includes several promising candidates designed to address various types of cancer:
Innovative Product Candidates
1. **ORIC-114**: A first-in-class brain-penetrant inhibitor that specifically targets EGFR exon 20 and HER2 exon 20 mutations, this therapy is being developed for multiple genetically defined cancers.
2. **ORIC-944**: This novel allosteric inhibitor targets the polycomb repressive complex 2 (PRC2) via the EED subunit and is under development for prostate cancer treatment.
3. **ORIC-533**: An orally bioavailable small molecule that inhibits CD73, involved in resistance to chemotherapy and immunotherapy, currently in development for multiple myeloma.
In addition to these leading candidates, ORIC is actively pursuing other precision medicines aimed at tackling various resistance mechanisms associated with cancer treatments.
Company Commitment and Vision
ORIC's commitment to enhancing patient outcomes through innovative treatments underscores its role in the biotechnology sector. The ongoing development of therapies designed to overcome resistance signifies a step forward for cancer patients facing challenging circumstances.
Connect with ORIC Pharmaceuticals
To learn more about ORIC Pharmaceuticals and their initiatives, you can visit their official site and follow them across social media platforms. They are dedicated to keeping investors and stakeholders informed about their journey toward making a significant impact in oncology.
Frequently Asked Questions
What is ORIC Pharmaceuticals known for?
ORIC Pharmaceuticals focuses on developing innovative oncology treatments that aim to overcome mechanisms of therapeutic resistance.
What conferences is ORIC participating in this November?
ORIC will participate in Guggenheim's Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference.
How can investors access the conference discussions?
Investors can access live webcasts of the discussions through the investor section of ORIC's website, with replays available for 90 days after the events.
What are ORIC's lead product candidates?
ORIC's lead product candidates include ORIC-114, ORIC-944, and ORIC-533, targeting various cancer types and mechanisms of resistance.
Where is ORIC Pharmaceuticals located?
ORIC Pharmaceuticals has offices in South San Francisco and San Diego, California.
